INTRODUCTION {#s1}
============

Gastric cancer, one of the most common cancers worldwide, is the second leading cause of cancer deaths \[[@R1], [@R2]\]. An estimated 679,100 cases of gastric cancer were diagnosed and 498,000 deaths occurred in China in 2015 \[[@R3]\]. Early detection and radical surgery have increased the survival of patients with gastric cancer. However, the prognosis of patients in advanced stages of gastric cancer is unfavorable because of the lack of efficient adjuvant therapy \[[@R4], [@R5]\]. Novel molecules from medicinal plants that have higher efficacy and lower toxicity when combined with traditional chemotherapeutics can be identified \[[@R6], [@R7]\].

Ursolic acid (UA) (Figure [1](#F1){ref-type="fig"}), a pentacyclic triterpenoid, has been identified from a variety of fruits, such as apples and cranberries, and from the herb basil. UA inhibits the growth of gastric cancer cells and colon cancer cells \[[@R8]--[@R10]\]. In animal models, UA inhibited tumorigenesis \[[@R11]\] and suppressed tumor invasion and metastasis \[[@R12], [@R13]\]. We found that UA induces apoptosis via down-regulation of cyclooxygenase-2 (COX-2) in gastric cancer cells \[[@R10]\]. COX-2 is expressed in gastric cancer and is a factor in cancer cell proliferation and apoptosis, cancer invasiveness, and metastasis \[[@R14], [@R15]\]. Studies have shown that COX-2 inhibition by selective COX-2 inhibitors or small interfering RNA (siRNA) suppresses cell growth and leads to apoptosis in human gastric adenocarcinoma cells \[[@R16], [@R17]\]. Moreover, studies have demonstrated the chemosensitization effect of UA combined with commonly used chemotherapeutics such as gemcitabine, cisplatin, and capecitabine \[[@R18]--[@R20]\]. For example, Prasad et al. \[[@R18]\] reported that UA inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine.

![The chemical structures of UA (molecular formula C~30~H~48~O~3~, and 456\
711 g/mol molecular weight) and PTX (molecular formula C~47~H~51~NO~14~, and 853.918 g/mol molecular weight).](oncotarget-08-92770-g001){#F1}

Paclitaxel (PTX) (Figure [1](#F1){ref-type="fig"}) is a promising cytotoxic agent. It acts through tubulin binding, thus disrupting DNA duplication \[[@R21]\]. PTX has been approved by FDA as a first-line chemotherapy regimen for a series of solid tumors, including gastric cancer \[[@R22], [@R23]\]. However, like most chemotherapeutic regimens, PTX has serious side effects, including peripheral nervous system toxicity \[[@R24]\], because of insufficient selectivity.

A phase II trial reported that the addition of a selective COX-2 inhibitor might enhance the response to preoperative PTX and carboplatin in patients with non-small-cell lung cancer \[[@R25]\]. Ferrandina et al. \[[@R26]\] reported that the expression of COX-2 is closely related to the sensitivity to PTX. Therefore, combined application of COX-2 specific inhibitor is a promising strategy to achieve better efficacy of PTX \[[@R27]\].

In the present study, human gastric cancer cell lines BGC-823 and SGC-7901, in which COX-2 is expressed \[[@R14]\], were utilized to investigate the antitumor effects of UA in combination with PTX in human gastric cancer *in vitro*. In addition, COX-2 expression, proliferating cell nuclear antigen (PCNA), and apoptosis-related proteins were detected, further elucidating the possible mechanism underlying the antitumor effects of UA and PTX in gastric cancer.

RESULTS {#s2}
=======

Effects of UA and PTX on BGC-823 and SGC-7901 cell proliferation {#s2_1}
----------------------------------------------------------------

The MTT assay is commonly utilized to evaluate the survival of cells exposed to different therapeutics. UA (Figure [2A](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}) and PTX (Figure [2B](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}) both time-dependently and dose-dependently inhibit cell proliferation. Figure [2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"} show that simultaneous administration of UA and PTX increases cytotoxicity more than either of the single agents alone. As shown in Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}, the combination-index (CI) method was utilized to evaluate the synergy of UA and PTX *in* inhibiting *proliferation* of BGC-823 and SGC-7901 cells. The CI was less than 1 at each fraction, which indicates a synergistic anti*proliferation* effect of UA and PTX. In addition, isobologram analysis was performed to confirm the results in Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}. When the dose of UA is fixed at 4 and 8 μmol/L for the combination, the IC~50~ value of PTX at two combinational doses, which was lower than PTX used alone, is located inside the triangle area of Figure [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}. Therefore, Figure [3](#F3){ref-type="fig"} reveals a significant synergistic effect of UA and PTX in BGC-823 (Figure [3A](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}) and SGC-7901 cells (Figure [3B](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}).

![Effects of UA and PTX on BGC-823 and SGC-7901 cell proliferation\
**(A)** Dose-dependent and time-dependent effects of UA on BGC-823 cell proliferation. **(B)** Dose-dependent and time-dependent effects of PTX on BGC-823 cell proliferation. **(C)** Dose-dependent and time-dependent effects of UA on SGC-7901 cell proliferation. **(D)** Dose-dependent and time-dependent effects of PTX on SGC-7901 cell proliferation. **(E)** Effects of UA in combination with PTX on BGC-823 cell proliferation. **(F)** Effects of UA in combination with PTX on SGC-7901 cell proliferation. BGC-823 and SGC-7901 cells were treated with various concentrations of UA and PTX, or the combinations of the two agents for 24, 48, or 72 hours. The results are expressed as the percentages of the control. Data are shown as mean ± SD from three independent experiments. ^\*\*^*P*\< 0.01 vs. control.](oncotarget-08-92770-g002){#F2}

![The combination of UA and PTX is synergistic in inhibiting proliferation of BGC-823 and SGC-7901 cells\
**(A** and **B)** The combination index for each fraction-affected value (Fa) was calculated by use of the Chou-Talalay method. **(C** and **D)** Representative isobologram of the treatment of BGC-823 and SGC-7901 **cells** with a combination of UA and PTX.](oncotarget-08-92770-g003){#F3}

Effects of UA and PTX on the apoptosis of BGC-823 and SGC-7901 cells {#s2_2}
--------------------------------------------------------------------

BGC-823 and SGC-7901 cells were treated with UA (12 μmol/L), PTX (2.5 nmol/L), or both for 48 hours and stained with acridine orange/ethidium bromide (AO/EB) to identify different stages of apoptosis through apoptosis-associated characteristics of cellular membranes. Normally, early apoptosis is characterized by granular or crescent shaped yellow to green AO staining, and late apoptosis is characterized by concentrated and asymmetrically localized orange nuclear EB staining. Necrotic cells are indicated by uneven orange-red fluorescence. As shown in Figure [4A](#F4){ref-type="fig"}, the control cells exhibited homogenous chromatin morphology, with no sign of apoptosis. UA-treated or PTX-treated cells exhibited early and late apoptosis as well as necrosis. Combined treatment induces more apoptosis or necrosis than either of the two agents alone. In addition, apoptosis was evaluated by annexin V/*propidium iodide* (PI) double staining and flow cytometry. In Figure [4B](#F4){ref-type="fig"}, the lower right panels correspond to cells with apoptosis showing bright fluorescein isothiocyanate (FITC) and dark PI signals. Both UA and PTX led to apoptosis in BGC-823 and SGC-7901 cells, and the combined application of the two agents had stronger apoptotic induction (Figure [4C](#F4){ref-type="fig"}).

![Effects of UA and PTX on the apoptosis of BGC-823 and SGC-7901 cells\
Cells were treated with 12 μM UA, 2.5 nM PTX, or both for 48 hours. **(A)** Morphological changes in apoptotic cells were examined by fluorescence microscopy after AO/EB dual staining. **(B)** Flow cytometry-based annexinV-FITC/PI labeling of apoptotic cells. **(C)** The histogram at the bottom represents the mean ± SD of apoptosis rates obtained from three independent experiments. ^\*\*^*P* \< 0.01 vs. control and ^++^*P* \< 0.01 vs. UA or PTX.](oncotarget-08-92770-g004){#F4}

Effects of UA and PTX on the expression of COX-2, PCNA, Bcl-2, and Bax in BGC-823 and SGC-7901 cells {#s2_3}
----------------------------------------------------------------------------------------------------

To study the effect of UA and PTX on cell proliferation and apoptosis induction, expressions of COX-2 (involved in proliferation and apoptosis), PCNA (involved in proliferation), Bcl-2, and Bax (involved in apoptosis) in BGC-823 (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}) and SGC-7901 cells (Figure [5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}) were evaluated by Western blot analysis. The results showed that UA or PTX suppressed COX-2, PCNA, and Bcl-2 expressions but increased Bax expression in BGC-823 and SGC-7901 cells. UA in combination with PTX inhibited COX-2, PCNA, and Bcl-2 expression and induced Bax expression more than either agent alone.

![Effects of UA and PTX on the COX-2, PCNA, Bcl-2, and Bax expression in BGC-823 and SGC-7901 cells\
Cells were treated with 12 μM UA, 2.5 nM PTX, or both for 48 hours. **(A** and **C)** COX-2, PCNA, Bcl-2, and Bax expression was detected by Western blot analysis. **(B** and **D)** The histogram represents the relative expressions of COX-2, PCNA, Bcl-2, and Bax compared with GAPDH. Each data point represents the mean ± SD from three independent experiments. ^\*^*P* \< 0.05, ^\*\*^*P*\< 0.01 vs. control; ^+^*p* \< 0.05, ^++^*p* \< 0.01 vs. UA or PTX; and ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. UA.](oncotarget-08-92770-g005){#F5}

DISCUSSION {#s3}
==========

Chemotherapy is the main treatment option for patients with advanced stage gastric cancer. Although PTX is frequently used in patients with gastric cancer \[[@R28], [@R29]\], this agent has limited efficacy and has side effects \[[@R24]\].

Combined application of different chemotherapeutics is currently the main treatment strategy in clinical settings. Studies have demonstrated the potential of herbal medicine as a novel adjuvant for chemotherapy that effectively enhances the antitumor effect of chemotherapeutics (PTX, cisplatin, etc.) \[[@R30], [@R31]\]. Our study has shown that UA induces apoptosis of gastric cancer cells by down-regulation of COX-2 \[[@R10]\]. Moreover, *in vivo* evaluation in a xenograft model of gastric cancer confirmed the antitumor effect of UA \[[@R32]\], which suggests that UA might have the potential of chemosensitization. The rationale for the combination of UA and PTX is based on the synergism between the two agents. Moreover, the synergism is dependent on the inhibition of COX-2 expression by UA, which is a factor in the reversal of PTX resistance, as reported previously \[[@R26]\].

Therefore, we investigated whether UA derived from various plant sources has potential either alone or in combination with PTX in the treatment of gastric cancer. He et al. \[[@R33]\] reported that UA showed synergistically hypoglycemic acitivity with other agents by scavenging excess intracellular reactive oxygen species. No synergistic antitumor effects of UA with other chemotherapeutics have been reported. Results from the current report have proved the dose-dependent and time-dependent inhibitory effects of UA on cell proliferation, which is in accordance with previous studies \[[@R32], [@R34]\]. UA in combination with PTX exerted synergistic anticancer effects *in vitro*. No study has previously reported the synergistic antitumor effect of UA combined with PTX. This study is the first to demonstrate the chemosensitization effect of UA in gastric cancer.

To elucidate the possible mechanism by which UA inhibits the proliferation of gastric cancer cells, expression of proliferating cell nuclear antigen (PCNA) was detected by Western blot analysis. Our results showed that UA and PTX reduced PCNA expression in BGC-823 and SGC-7901 cells. PCNA, one of the nuclear proteins, is produced in late G1 and S phases of the cell cycle and is often used as an indicator of changes in cellular proliferative status \[[@R14], [@R35]\]. PCNA expression is an indicator of early changes in cellular proliferation and possibly promotes the inhibitory effect on cell proliferation by UA, PTX, or both. In our previous study, co-treatment with NS-398, a selective COX-2 inhibitor, reversed the inhibitory effect on PCNA expression in human pancreatic cancer cells \[[@R35]\]. The suppressive effect on cell proliferation by UA or PTX is possibly induced by the prevention of COX-2 inducing PCNA expression in gastric adenocarcinoma cells.

Our previous study showed that UA can decrease the expression of COX-2 in gastric cancer cells \[[@R10]\]. Both *in vitro* and *in vivo* results from previous studies have shown that the elevated expression of COX-2 counteracts the apoptosis induced by the increase of Bcl-2 expression \[[@R36], [@R37]\]. The treatment with NS-398 is effective in inhibiting the expression of Bcl-2 while promoting the expression of Bax in human gastric cancer cells \[[@R17]\]. These results indicate that apoptosis induced by UA, PTX, or both is most likely linked to the down-regulation of COX-2 protein in gastric cancer cells. Studies have reported that inhibition of COX-2 reverses the resistance of several types of cancer cells to PTX \[[@R38], [@R39]\]. Additionally, studies have shown that inhibition of COX-2 expression leads to apoptosis in cancer cells by stimulating pro-apoptotic proteins \[[@R40], [@R41]\]. Thus, down-regulation of COX-2 and the consequent activation of apoptosis is a way to sensitize gastric cancer cells to PTX.

This study demonstrates that UA, a naturally occurring triterpenoid, can enhance the antitumor effect of PTX on gastric cancer cells through the down-regulation of COX-2, the decrease of the ratio of Bcl-2/Bax, and the consequent induction of apoptosis. Although UA has not been approved for clinical application, it is an effective and low-toxic adjuvant for PTX in the treatment of gastric cancer.

MATERIALS AND METHODS {#s4}
=====================

Drugs and reagents {#s4_1}
------------------

UA, PTX, Methyl thiazolyl tetrazolium (MTT), dimethyl sulfoxide (DMSO), and 4′,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma-Aldrich Chemical Company (St. Louis, MO, USA). Stock solutions of UA and PTX were made in DMSO at 0.1% final concentration and sterilized by passage through a 0.22-μm filter (Immobilon, Millipore Corp., Bedford, MA, USA), diluted with culture media before use. RPMI-1640 medium, fetal bovine serum (FBS), and penicillin/streptomycin were purchased from Gibco BRL (Grand Island, NY, USA). Other reagents were of analytic grade and obtained from Nanjing Chemical Reagent Company (Nanjing, China), unless otherwise described.

Cell lines and culture conditions {#s4_2}
---------------------------------

The poorly differentiated human gastric cancer cell line BGC-823 and the moderately differentiated gastric cancer cell line SGC-7901 were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences, Shanghai Institute of Cell Biology (Shanghai, China). The cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/mL penicillin G, and 100 μg/mL streptomycin at 37°C in a humidified incubator with 5% CO~2~.

Methyl thiazolyl tetrazolium cell viability assay {#s4_3}
-------------------------------------------------

BGC-823 and SGC-7901 cells were seeded onto 96-well microplates at a density of 5 × 10^3^ cells per well and incubated overnight in 10% FBS medium. The cells were then treated with different concentrations of UA or PTX in serum-free conditions. After incubation for 24, 48, and 72 hours at 37°C, cell viability was determined by the MTT assay as described in our previous study \[[@R17], [@R35]\]. Each experiment was performed in triplicate. The results were presented as the percentages relative to the control cells treated with 0.1% DMSO. The 50% inhibitory concentration (IC~50~) was calculated by use of the dose-response curve.

Analysis of combined effects {#s4_4}
----------------------------

The combined effects of UA plus PTX were assessed by the combination-index (CI) method \[[@R42]\] and isobologram analysis \[[@R43]\]. On the basis of the dose-response curves utilizing the MTT assay, the CI is defined by the following equation: CI = (D)~1~/(Dx)~1~ + (D)~2~/(Dx)~2~ + (D)~1~(D)~2~/(Dx)~1~(Dx)~2~, where (D)~1~ and (D)~2~ are the concentrations of UA and PTX that exhibit a determined effect when applied simultaneously to the cells, and (Dx)~1~ and (Dx)~2~ are the concentrations of UA and PTX that exhibit the same determined effect when used in isolation. From this analysis, the combined effects of UA and PTX can be summarized as follows: CI \< 1, CI = 1, and CI \>1 indicates synergistic, additive, and antagonistic effects, respectively. The isobologram is formed by plotting the individual agent concentrations required to achieve 50% inhibitory effect on their respective x-axes and y-axes. A straight line connecting the two points is drawn, and the concentrations of the two agents used in combination to achieve 50% inhibitory effect are plotted on the isobologram. Combination data points that fall on the line represent an additive interaction, whereas data points that fall below or above the line represent synergism or antagonism, respectively.

Acridine orange/ethidium bromide dual staining {#s4_5}
----------------------------------------------

AO/EB dual staining was used to evaluate the apoptosis-inducing effect. Equal numbers of BGC-823 and SGC-7901 cells (1 × 10^5^) were plated in 24-well dishes, and then incubated with 12 μM UA, 2.5 nM PTX, or a combination of these two agents for 48 hours. The cells were washed in phosphate buffer saline (PBS), and then subjected to trypsin digestion. Cell suspension was transferred to glass clips with the addition of dual fluorescent staining solution (1 μL) containing 100 μg/mL AO and 100 μg/mL EB (Sigma, St. Louis, MO) and subsequently examined by fluorescence microscopy (Eclipse E-800; Nikon, Tokyo, Japan).

Flow cytometry analysis {#s4_6}
-----------------------

For further quantitative analysis of apoptosis, the cells were washed with PBS and stained with annexinV-FITC and propidium iodide (PI) by use of an AnnexinV-FITC kit (Bender Medsystem, Vienna, Austria). The cells were then subjected to flow cytometry according to the manufacturer\'s instructions, and the stained cells were analyzed by FACScan flow cytometer (Becton Dickinson, CA, USA).

Western blot analysis {#s4_7}
---------------------

Preparation of cell lysates and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis was performed as described in our previous reports \[[@R14], [@R17]\]. Primary antibodies used include rabbit anti-COX-2, anti-Bcl-2, anti-Bax (Cell Signaling Technology, Inc., Beverly, MA, USA), anti-PCNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti-GAPDH (Sigma-Aldrich). Goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody was purchased from Vector Laboratories Inc. (Burlingame, CA, USA). Bands were quantified by application of densitometric image analysis software (Quantity One, Bio-Rad, Hercules, CA, USA). The relative expressions of COX-2, PCNA, Bcl-2, and Bax were normalized to that of GAPDH.

Statistical analysis {#s4_8}
--------------------

Statistical analyses were done by SPSS Version 17.0 software (SPSS Inc., Chicago, IL, USA). The data are shown as means ± standard deviation (SD). Statistical comparison among the groups was analyzed by use of ANOVA, followed by Fisher\'s least significant difference test. *P* \< 0.05 was considered statistically significant.
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